Concizumab

For research use only. Not for therapeutic Use.

  • CAT Number: I042255
  • CAS Number: 1312299-39-0
  • Purity: ≥95%
Inquiry Now

Concizumab(Cat No.:I042255)is a monoclonal antibody designed to target and inhibit tissue factor pathway inhibitor (TFPI), a protein involved in regulating blood clotting. By blocking TFPI, Concizumab enhances the activation of the coagulation cascade, potentially improving clot formation. This makes it a promising therapeutic candidate for patients with hemophilia, a condition characterized by deficient blood clotting. In clinical trials, Concizumab has shown potential in preventing bleeding episodes in hemophilia patients, offering an alternative to traditional factor replacement therapies.

Request a Quote